Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats

被引:21
作者
Satoh, S
Ikegaki, I
Toshima, Y
Watanabe, A
Asano, T
Shimokawa, H
机构
[1] Asahi Kasei Corp, Life Sci Res Inst, Lab Pharmacol 1, Ohito 4102321, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan
关键词
angina; fibrosis; Rho-kinase inhibitor; fasudil;
D O I
10.1016/S0024-3205(02)02178-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of this study was to develop a new model of vasopressin-induced chronic myocardial damage based on sustained ST-segment depression in electrocardiogram (ECG) with progression of myocardial fibrosis in rats. Furthermore, using this model, we examined the prophylactic potential of fasudil, a Rho-kinase inhibitor, against myocardial damage induced by vasopressin. In 10-week old male Donryu rats, intravenous administration of arginine vasopressin (0.5 iu/kg) induced significant ST-segment depression. Two days and one week after the administration of vasopressin, ST-segment depression was -0.19 +/- 0.02 and -0.14 +/- 0.02 mV, respectively. Fasudil (10 and 30 mg/kg, p.o.) significantly attenuated the ST-segment depression induced by vasopressin. One week after the administration of vasopressin, the percent area of myocardial fibrosis in control animals (0.42 +/- 0.11%, p < 0.01) was significantly greater than that in normal animals (0.05 +/- 0.01%). Fasudil (10 and 30 mg/kg) significantly prevented the development of the fibrosis. We present a new model of chronic myocardial damage based on sustained ST-segment depression with progression of myocardial fibrosis in rats, and suggest that this model may be useful to investigate the treatment of chronic angina. Inhibition of Rho-kinase is efficacious in preventing the ECG change and development of fibrosis induced by vasopressin in this model. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:103 / 112
页数:10
相关论文
共 50 条
  • [41] Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes
    Zhou Hong
    Fang Caixia
    Zhang Lihui
    Deng Yonggui
    Wang Mian
    Meng Fengling
    CHINESE MEDICAL JOURNAL, 2014, 127 (02) : 225 - 231
  • [42] Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease
    Nagai, Yosuke
    Matoba, Keiichiro
    Yako, Hideji
    Ohashi, Shinji
    Sekiguchi, Kensuke
    Mitsuyoshi, Etsuko
    Sango, Kazunori
    Kawanami, Daiji
    Utsunomiya, Kazunori
    Nishimura, Rimei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 649 : 32 - 38
  • [43] Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase
    Kast, R.
    Schirok, H.
    Figueroa-Perez, S.
    Mittendorf, J.
    Gnoth, M. J.
    Apeler, H.
    Lenz, J.
    Franz, J. K.
    Knorr, A.
    Huetter, J.
    Lobell, M.
    Zimmermann, K.
    Muenter, K.
    Augstein, K. H.
    Ehmke, H.
    Stasch, J. P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (07) : 1070 - 1080
  • [44] Super-selective intracoronary injection of Rho-kinase inhibitor relieves refractory coronary vasospasms: A case report
    Taniguchi, Yousuke
    Funayama, Hiroshi
    Matsuda, Jun
    Fujita, Kanna
    Nakagawa, Tom
    Nakamura, Tomohiro
    Umemoto, Tomio
    Mitsuhashi, Takeshi
    Ako, Junya
    Momomura, Shin-ichi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (01) : 270 - 271
  • [45] Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia
    Takase, Saeko
    Liao, Jingzhu
    Liu, Yue
    Tanaka, Rinako
    Miyagawa, Yasuhiro
    Sawahata, Masahito
    Sobue, Akira
    Mizoguchi, Hiroyuki
    Nagai, Taku
    Kaibuchi, Kozo
    Ozaki, Norio
    Yamada, Kiyofumi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 931
  • [46] Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia
    Kikuchi, Yoku
    Takahashi, Jun
    Hao, Kiyotaka
    Sato, Koichi
    Sugisawa, Jun
    Tsuchiya, Satoshi
    Suda, Akira
    Shindo, Tomohiko
    Ikeda, Shohei
    Shiroto, Takashi
    Matsumoto, Yasuharu
    Miyata, Satoshi
    Sakata, Yasuhiko
    Shimokawa, Hiroaki
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 297 : 8 - 13
  • [47] Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
    Loehn, Matthias
    Plettenburg, Oliver
    Ivashchenko, Yuri
    Kannt, Aimo
    Hofmeister, Armin
    Kadereit, Dieter
    Schaefer, Matthias
    Linz, Wolfgang
    Kohlmann, Markus
    Herbert, Jean-Marc
    Janiak, Philip
    O'Connor, Stephen E.
    Ruetten, Hartmut
    HYPERTENSION, 2009, 54 (03) : 676 - 683
  • [48] Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats
    Koshikawa, Shogo
    Nishikimi, Toshio
    Inaba, Chikako
    Akimoto, Kazumi
    Matsuoka, Hiroaki
    JOURNAL OF HYPERTENSION, 2008, 26 (09) : 1837 - 1848
  • [49] Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage
    Satoh, Shin-ichi
    Hitomi, Asako
    Ikegaki, Ichiro
    Kawasaki, Koh
    Nakazono, Osamu
    Iwasaki, Masakazu
    Mohri, Mitsunobu
    Asano, Toshio
    BRAIN RESEARCH BULLETIN, 2010, 81 (01) : 191 - 195
  • [50] Enhanced endothelin-1/Rho-kinase signaling and coronarymicrovascular dysfunction in hypertensive myocardial hypertrophy
    Merkus, Daphne
    Tune, Johnathan D.
    CARDIOVASCULAR RESEARCH, 2017, 113 (11) : 1273 - 1275